Colorectal cancer: pharmacogenetics support for the correct drug prescription.
clinical implementation
colorectal cancer
drug label
guidelines
pharmGKB
pharmacogenetics
polymorphisms
Journal
Pharmacogenomics
ISSN: 1744-8042
Titre abrégé: Pharmacogenomics
Pays: England
ID NLM: 100897350
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
2
8
2019
medline:
29
4
2020
entrez:
2
8
2019
Statut:
ppublish
Résumé
Pharmacogenetics (PGx) in clinical practice is a tool that the clinician can use to guide, in a personalized way, the most suitable treatment that will be administered to the patient. The objective of this review is to summarize in a practical and accessible rational way, the advances that currently exist for the application of PGx in colorectal cancer chemotherapy management through the study of the patients' germline polymorphisms. To define the polymorphisms that can be applied, we rely on three fundamental cornerstones: the recommendations of drug regulatory agencies; the implementation guidelines prepared by expert consortia in PGx and information from clinical annotations (the drug/polymorphism relation) according to the scientific level of evidence assigned by PharmGKB experts.
Identifiants
pubmed: 31368847
doi: 10.2217/pgs-2019-0041
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM